Digoxin Added After Acute Heart Failure Episodes

Trial details

Who runs it

Hospital General de Agudos "Dr. Cosme Argerich"

Trial code

NCT07321509

Record updated

2 June 2026

Original description

The DIG-DICA trial is a randomized, controlled, open-label, single-center study designed to evaluate whether adding low-dose digoxin to optimal medical therapy after an episode of acute decompensated heart failure improves patients' clinical status and quality of life. The study enrolls adults with heart failure with reduced ejection fraction (HFrEF) who have recently stabilized after hospitalization or urgent care for decompensation. The primary aim is to determine whether digoxin increases the proportion of patients who are "Alive and Well" at 180 days-defined by achieving a Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score ≥75. The trial also explores effects on symptoms, functional capacity, biomarkers, renal function, and major cardiovascular events. The goal is to clarify whether modern low-dose digoxin provides meaningful clinical benefit in contemporary heart failure management.Read full original descriptionShow less

Evaluation of Digoxin Therapy in Patients With Heart Failure After Acute Decompensation

The DIG-DICA trial is a randomized, controlled, open-label, single-center study designed to evaluate whether adding low-dose digoxin to optimal medical therapy after an episode of acute decompensated heart failure improves patients' clinical status and quality of life. The study enrolls adults with heart failure with reduced ejection fraction (HFrEF) who have recently stabilized after hospitalization or urgent care for decompensation. The primary aim is to determine whether digoxin increases the proportion of patients who are "Alive and Well" at 180 days-defined by achieving a Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score ≥75. The trial also explores effects on symptoms, functional capacity, biomarkers, renal function, and major cardiovascular events. The goal is to clarify whether modern low-dose digoxin provides meaningful clinical benefit in contemporary heart failure management.

Inclusion: Male or female ≥ 18 years of age who have signed written informed consent and are willing and able to complete treatment and follow-up; Recent hospitalization or emergency department visit for decompensated heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 40%); Resting heart rate ≥ 60 bpm in patients without a pacemaker; Distance walked on the 6-minute walk test (6MWT) ≤ 450 meters and/or less than 80% of the predicted value; NT-proBNP ≥ 450 pg/mL, or ≥ 900 pg/mL in patients with atrial fibrillation, and/or echocardiographic criteria of congestion; -.

Exclusion: Known hypersensitivity to digoxin (including prior adverse reactions); Current treatment with digoxin; Resting heart rate < 60 bpm in sinus rhythm or < 70 bpm in atrial fibrillation; Myocardial infarction, acute coronary syndrome, myocarditis, percutaneous coronary intervention, or recent implantation (within the past 3 months) of cardiac resynchronization therapy (CRT), pacemaker, or implantable cardioverter-defibrillator (ICD); cardiac surgery or stroke within the past 30 days; Planned implantation of a ventricular assist device or cardiac transplantation; Non-cardiac comorbidities with a limited life expectancy (less than or equal to the study duration); Non-cardiac conditions (neurological or orthopedic) preventing performance of the 6-minute walk test (6MWT); Presence of an accessory atrioventricular conduction pathway (e.g., Wolff-Parkinson-White syndrome); History of symptomatic or sustained ventricular tachyarrhythmia (≥ 30 seconds); Severe aortic valvular disease (grade III/III) with indication for invasive treatment; Complex congenital heart disease; Estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m² (based on a sample obtained within the previous month); Presence of a mechanical ventricular assist device; Body mass index (BMI) ≥ 35 kg/m²; Amyloid, hypertrophic obstructive, or constrictive cardiomyopathy; Intermittent complete atrioventricular block or Mobitz type II second-degree AV block without pacemaker or ICD; Participation in another clinical trial (excluding observational registries); Pregnant or breastfeeding women, or women with the potential to become pregnant during the study period; -.

ClinicalTrials.gov NCT07321509